Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRL 
Charles River Laboratories (CRL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: CRL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $189.27
1 Year Target Price $189.27
| 4 | Strong Buy |
| 0 | Buy |
| 14 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.66% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.60B USD | Price to earnings Ratio - | 1Y Target Price 189.27 |
Price to earnings Ratio - | 1Y Target Price 189.27 | ||
Volume (30-day avg) 19 | Beta 1.64 | 52 Weeks Range 91.86 - 202.72 | Updated Date 12/3/2025 |
52 Weeks Range 91.86 - 202.72 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When Before Market | Estimate 2.35 | Actual 2.43 |
Profitability
Profit Margin -2.05% | Operating Margin (TTM) 15.77% |
Management Effectiveness
Return on Assets (TTM) 4.34% | Return on Equity (TTM) -2.19% |
Valuation
Trailing PE - | Forward PE 16.39 | Enterprise Value 11087893288 | Price to Sales(TTM) 2.14 |
Enterprise Value 11087893288 | Price to Sales(TTM) 2.14 | ||
Enterprise Value to Revenue 2.76 | Enterprise Value to EBITDA 21.47 | Shares Outstanding 49215471 | Shares Floating 48630791 |
Shares Outstanding 49215471 | Shares Floating 48630791 | ||
Percent Insiders 1 | Percent Institutions 106.74 |
Upturn AI SWOT
Charles River Laboratories
Company Overview
History and Background
Charles River Laboratories was founded in 1947 by Henry Foster as a small laboratory breeding laboratory animals. It has grown through strategic acquisitions and organic expansion to become a leading global provider of drug discovery and development services.
Core Business Areas
- Research Models and Services (RMS): Provides laboratory animal models and related services, including breeding, genetic characterization, and health monitoring.
- Discovery and Safety Assessment (DSA): Offers integrated drug discovery and safety assessment services, including target identification, lead optimization, toxicology, and pathology.
- Manufacturing Solutions (Manufacturing): Provides microbial solutions, biopharmaceutical manufacturing and testing support.
Leadership and Structure
James C. Foster serves as Chairman, President, and Chief Executive Officer. The company operates with a global organizational structure, with regional and functional divisions.
Top Products and Market Share
Key Offerings
- Research Models: Genetically defined laboratory animals (primarily rodents) used in preclinical research. Estimated market share within animal models is around 25-30%. Competitors: Envigo (acquired by Inotiv), Taconic Biosciences, The Jackson Laboratory.
- Safety Assessment Services: Toxicology and safety testing of drugs and chemicals for regulatory submission. Estimated market share is significant but fragmented; specific numbers are difficult to ascertain. Competitors: Envigo (Inotiv), WuXi AppTec, Labcorp Drug Development (Covance).
- Biopharmaceutical Manufacturing: Provides CDMO services, contract manufacturing support. Competitors: Catalent, Thermo Fisher Scientific (PPD), Lonza.
Market Dynamics
Industry Overview
The preclinical research and drug development market is growing, driven by increasing R&D spending, stricter regulatory requirements, and the need for innovative therapies. It involves animal models, drug discovery, and safety assessment.
Positioning
Charles River Laboratories is a leading player in the preclinical research and drug development market. It has a strong brand reputation, global presence, and comprehensive service offerings.
Total Addressable Market (TAM)
Estimated TAM for preclinical research and development services is estimated to be over $20 billion. Charles River is well-positioned to capture a significant share due to its breadth of services.
Upturn SWOT Analysis
Strengths
- Global presence
- Comprehensive service portfolio
- Strong brand reputation
- Established customer relationships
- Expertise in animal models and safety assessment
Weaknesses
- High operating costs
- Exposure to regulatory changes
- Dependence on pharmaceutical R&D spending
- Potential for ethical concerns related to animal testing
- Debt load from acquisitions
Opportunities
- Growing demand for preclinical research services
- Expansion into emerging markets
- Development of new technologies and service offerings
- Strategic acquisitions to expand capabilities
- Partnerships with pharmaceutical companies
Threats
- Increased competition
- Economic downturns
- Changes in regulatory requirements
- Ethical concerns related to animal testing
- Emergence of alternative testing methods
Competitors and Market Share
Key Competitors
- INVT
- WUXI
- LH
Competitive Landscape
Charles River Laboratories benefits from its comprehensive service offerings and global presence. Competition revolves around pricing, service quality, and technological innovation.
Major Acquisitions
Vigene Biosciences
- Year: 2021
- Acquisition Price (USD millions): 292.5
- Strategic Rationale: Expanded Charles River Laboratories capabilities in gene therapy CDMO services.
Growth Trajectory and Initiatives
Historical Growth: Charles River Laboratories has experienced significant growth through acquisitions and organic expansion in the past decade.
Future Projections: Future growth projections depend on market conditions and analyst estimates. Please review financial analysts data for the projection of future growth.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand capabilities and geographical reach, investments in technology, and expansion of service offerings.
Summary
Charles River Laboratories is a strong player in the preclinical research market, benefiting from its global presence and comprehensive services. Its growth is driven by strategic acquisitions and the expansion of its service portfolio. High operating costs, ethical concerns surrounding animal testing, and the debt it has taken on from acquisitions are concerns. To maintain its market position, the company needs to continue innovating and addressing ethical concerns.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial analysis websites
- Press releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Charles River Laboratories
Exchange NYSE | Headquaters Wilmington, MA, United States | ||
IPO Launch date 2000-06-23 | Chairman, President & CEO Mr. James C. Foster J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18700 | Website https://www.criver.com |
Full time employees 18700 | Website https://www.criver.com | ||
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. In additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.